Earnings
Aquestive CEO Counts Down To FDA Decision: 132 Days, Or 88 Trading Days
Management calls speed Anaphylm's differentiator, keeps its pricing private and holds 2026 revenue guidance of $46 million to $50 million.
Aquestive Therapeutics (AQST) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management calls speed Anaphylm's differentiator, keeps its pricing private and holds 2026 revenue guidance of $46 million to $50 million.
Earnings
The drugmaker's cash fell to $90.3 million as lower Suboxone orders cut third-quarter revenue to $7.6 million.
SEC Filings
The drugmaker kept its 2026 outlook and ended September with $90.3 million in cash as it prepares to launch Anaphylm if approved.
SEC Filings
The board rewrote its bylaws on October 15, cutting what a stockholder must say about ties when nominating directors.
Earnings
The agency accepted the resubmission as a Class 2 response, and Aquestive still plans a Canadian filing in the fourth quarter.
SEC Filings
The license adds up to $47.5 million in milestones and mid-teens royalties, with launch targeted for April 2027 pending final FDA approval.
SEC Filings
A Schedule 13G lists Bass with sole voting and selling power over 9,385,561 shares and certifies no intent to influence control.